Skip to Main Content

Moderna, racing to develop a vaccine for Covid-19, lost a key patent decision Thursday, one that could delay the company’s progress or force it to hand over a cut of profits.

The U.S. Patent and Trademark Office denied Moderna’s claim that a patent held by a rival company was invalid. The patent, which covers technology used to deliver messenger RNA treatments, is held by the Canadian firm Arbutus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • This could be good news for Matinas Biopharma (MTNB) that has a superior liquid crystal nano delivery system that could potentially be used in place of the inferior LNP delivery system of Arbutus.

    MTNB is up 20% today is very heavy volume.

Comments are closed.